Short interest has gone up with ATHX but so have long term holders in this, including me. ATHX is significantly undervalued with a $100M market cap, $20M+ in cash, $30M in milestone payments due from RTI biologics, revenues to start with RTI biologics partnership, ATHX is in partnership discussions for their obesity drug, ATHX is in partnership discussions for other MultiStem indications, phase 2 IBD data is due with Pfizer partnership later this year (and OSIR obtained favorable results for a similar platform), the stroke results are coming out probably 1st quarter 2014 since ATHX is expediting enrollment which could generate billions if successful.... plus other possibilities.... so lots going on here. I wrote 3 articles on ATHX which are on SeekingAlpha. Im also on Twitter @BioInvestor71. I am LONG ATHX and will continue to accumulate.
There will always be profit taking... however, I personally think we see a partnership announcement any time now whether it be for another MultiStem indication or for obesity drug. Company has been publicly stating they have been in active discussions and this is a priority. I personally think the selling is from shorts since the short position has increased. I personally think most people who are in this are for the long term and bigger gains so I think there are less traders... as is my position. I think the shorts will be surprised when they have to start covering on news, partnerships, anticipation to study results etc and there are not many sellers... Anyways, my thoughts... we shall see.